NGS Panel Expansion (MyAML, MyMRD)

About InVivoScribe

Founded in 1999 and headquartered in San Diego, CA, InVivoScribe has established itself as a pioneer in precision diagnostics for hematologic malignancies. The company operates a dual business model, offering both a portfolio of regulated diagnostic products (CE-IVD, IVD) and a global network of CLIA-certified clinical laboratories (LabPMM). Its core strength lies in its proprietary assays for biomarkers like FLT3 and NPM1, its role as a streamlined CDx development partner for pharma, and its leadership in MRD testing, positioning it at the intersection of diagnostics, personalized medicine, and drug development support.

Therapeutic Areas

Other Hematologic Cancers Drugs